Table 2.
Middle ring modified EP2 antagonists. Potency and aqueous solubilitya
| Entry | ![]() |
EP2 KB (nM) | Aqueous Solubilityb (μM) | Solubility in SGF c (μM) |
|---|---|---|---|---|
| 2a | ![]() |
28.6 | 70 | ND |
| 2b | ![]() |
118 | 206 | ND |
| 2c | ![]() |
185 | ND | ND |
| 8a | ![]() |
23.2 | 25 | >100 |
| 8b | ![]() |
9.5 | 13 | >100 |
| 8c | ![]() |
10 | 28 | >100 |
| 8d | ![]() |
11.5 | 8 | 50c |
| 8e | ![]() |
48.4 | 22 | >100 |
| 8f | ![]() |
4.4 | 25 | >100 |
| 8g | ![]() |
2.9 | 12 | >100 |
| 11a | ![]() |
48.6 | 14 | 14 |
| 11b | ![]() |
33.6 | 10 | 10 |
| 11c | ![]() |
12.8 | 10 | 10 |
| 14a | ![]() |
29.6 | 71 | >100 |
| 14b | ![]() |
250 | 10 | 10d |
| 14c | ![]() |
7.7 | 5 | ND |
The potency of the compounds is presented in the form of Schild KB values, which are calculated using the formula log (dr-1) = log XB −log KB, where dr (dose ratio) = fold shift in EC50 of PGE2 by the antagonist compound, XB is antagonist concentration 1 μM. KB value indicates a concentration required to produce a 2-fold rightward shift of PGE2 EC50. KB values are average of 2 measurements run in duplicate.
The solubility of the compounds is measured in PBS buffer (pH 7.4) with 1% DMSO by nephelometry.46
The numbers are derived by measuring solubility in simulated gastric fluid (SGF) at pH 2.0 with 1% DMSO by nephelometry.
















